Stock Price & Analysis

Based on the analysis of IQVIA Holdings Inc. (IQV), here is a concise recommendation:

Buy IQV stock as it has strong analyst support and potential upside.

IQV stock is predicted to reach $244.41 by 2025, based on average analyst targets. The stock shows resilience with a 2.8% increase post-earnings, driven by strong TAS segment growth and a robust R&DS backlog. However, some analysts remain cautious due to market uncertainties.

The S1 support level for IQV Stock is $171.68 ,The R1 resistant level for IQV Stock is $186.41.

As of the end of day on 2025-04-02, the price of IQV Stock was $167.99.

The target price for IQV Stock according to analyst rating is 245.92, with the highest price target at 270.00 and the lowest at 210.00. Analysts have a Strong Buy rating on IQV Stock overall.

The market cap of IQV is $30.7B.

IQV may be overvalued based on its high valuation multiples and recent price trends. Here's the analysis:

1. Valuation Metrics: IQV's forward P/E ratio is elevated compared to industry peers, suggesting high expectations are priced in.
2. Analyst Sentiment: While some analysts see upside, the current price reflects optimism that may not materialize.
3. Technical Indicators: The stock shows signs of consolidation, with RSI around 45, indicating it's not overbought but lacks strong upward momentum.

IQVIA Holdings Inc. is a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. The Company's Connected Intelligence delivers insights enabling customers to accelerate the clinical development and commercialization of medical treatments that improve healthcare outcomes for patients. The Company operates through three segments: Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. Technology & Analytics Solutions provides mission critical information, technology solutions and real-world insights and services to life science clients. Research & Development Solutions primarily serves biopharmaceutical clients, provides outsourced clinical research and clinical trial services. Contract Sales & Medical Solutions provides health care provider (including contract sales) and patient engagement services to both biopharmaceutical clients and the broader healthcare market.

Price Prediction for IQV Stock by 2030

Based on current trends and analyst expectations, IQV stock is predicted to reach $300 by 2030. This forecast considers the company's strong fundamentals, including its leadership in the life sciences sector and growing demand for its technology and analytics solutions. Analysts have set price targets ranging from $210 to $273, with a consensus that IQVIA will continue to outperform due to its solid backlog and bookings growth. The stock's current price of $184.79 as of March 24, 2025, supports a long-term bullish outlook.

IQV has a total of 87000 employees.